31 completed, 11 terminated, 3 withdrawn, 1 active not recruiting. 31 Phase 2, 18 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Completed 20, Terminated 7, Withdrawn 3, Recruiting 1 |
| Phase 1 | 18 | Completed 12, Terminated 4, Active not recruiting 1, Unknown 1 |
Follow MK 2206: new trials by email Literature Review of MK 2206 trials Research Report on MK 2206
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study - Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2013-03-01 | 2019-09-20 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2013-01-15 | 2017-08-22 |
| Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate - Estrogen Receptor Positive, HER2/Neu Negative | Phase 2 | Terminated | National Cancer Institute (NCI) | 16 | 2013-01-01 | 2018-05-08 |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis - Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2013-01-01 | 2014-09-09 | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate - Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 60 | 2012-09-01 | 2013-09-30 |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Akt Inhibitor MK2206, Fluorouracil, Oxaliplatin - Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 137 | 2012-08-01 | 2016-03-09 |
| Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Akt Inhibitor MK2206, Laboratory Biomarker Analysis - Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2012-07-23 | 2019-05-01 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-01-01 | 2014-06-18 |
| Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2011-12-01 | 2017-09-28 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Akt Inhibitor MK2206, Hydroxychloroquine - Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2011-11-23 | 2026-09-09 |
| Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma MK2206 - Diffuse Large B Cell Lymphoma | Phase 2 | Terminated | Centre Leon Berard | 22 | 2011-11-01 | 2014-07-10 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Akt Inhibitor MK2206, Bendamustine Hydrochloride, Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2011-09-01 | 2017-09-15 |
| MK-2206 in Recurrent Nasopharyngeal Carcinoma MK-2206 - Recurrent Nasopharyngeal Carcinoma | Phase 2 | Completed | Chinese University of Hong Kong | 12 | 2011-07-01 | 2017-01-13 |
| BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer Erlotinib, AZD6244, MK-2206 - Lung Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 334 | 2011-06-02 | 2022-01-12 |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer Akt Inhibitor MK2206, Anastrozole, Fulvestrant - Estrogen Receptor Positive, Invasive Breast Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2011-04-21 | 2018-07-23 |
| A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis - Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2011-04-01 | 2016-06-24 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Akt inhibitor MK2206 - Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2011-04-01 | 2017-12-05 |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-04-01 | 2016-06-17 |
| MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2011-04-01 | 2017-08-30 |
| Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer Akt Inhibitor MK2206, Bicalutamide, Clinical Observation - Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 108 | 2011-03-17 | 2026-06-25 |
Showing 20 of 48. Sign in to see all of them.
Breast Neoplasms (12) · Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Lymphoma, Large B-Cell, Diffuse (4) · Carcinoma, Hepatocellular (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Ovarian Neoplasms (3) · Breast Neoplasms, Male (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Gallbladder Neoplasms (2) · Intraocular Lymphoma (2) · Leukemia, Hairy Cell (2)
National Cancer Institute (NCI) (31) · Merck Sharp & Dohme LLC (7) · Memorial Sloan Kettering Cancer Center (2) · Centre Leon Berard (1) · Chinese University of Hong Kong (1) · Dana-Farber Cancer Institute (1) · M.D. Anderson Cancer Center (1) · National Taiwan University Hospital (1) · QuantumLeap Healthcare Collaborative (1) · University of California, San Francisco (1) · Vanderbilt-Ingram Cancer Center (1)
United States (35) · Canada (3) · France (2) · China (1) · Hong Kong (1) · Ireland (1) · Singapore (1) · Taiwan (1)
Cynthia Ma (2) · Funda Meric-Bernstam (2) · Tanios Bekaii-Saab (2) · Alan Ho (1) · Amye Tevaarwerk (1) · Anna C Ferrari (1) · Anthony El-Khoueiry, MD (1) · Arun Rajan, M.D. (1) · Brigette Ma (1) · Brigette Ma, MD, FRACP (1) · Chih-Hsin Yang, MD, Ph.D (1) · Devika Gajria (1) · Diane Reidy-Lagunes, MD,MS (1)
PMID 21796368, PMID 22025163, PMID 22198468, PMID 22623692, PMID 22649152, PMID 24252402, PMID 24387695, PMID 24583795, PMID 25239610, PMID 25290091, PMID 25516890, PMID 25667274, PMID 25827820, PMID 25931518, PMID 26028668, PMID 26084990, PMID 26213141, PMID 27406346, PMID 27406347, PMID 27978579, PMID 28851423, PMID 31277699, PMID 31714586, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 37947157, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112
N01CM00039 (5), P30CA016672 (5), U01CA062490 (4), N01CM00038 (3), N01CM00099 (3), N01CM62202 (3), N01CM00070 (2), N01CM00071 (2), P30CA006516 (2), P30CA015083 (2), P30CA033572 (2), U10CA032102 (2), U10CA180821 (2), U10CA180888 (2), UM1CA186716 (2)